Almotriptan malate

Cat. No.:	HY-B0383	
CAS No.:	181183-52-8	
Molecular Formula:	C ₂₁ H ₃₁ N ₃ O ₇ S	
Molecular Weight:	469.55	
Target:	5-HT Receptor	
Pathway:	GPCR/G Protein; Neuronal Signaling	
Storage:	4°C, sealed storage, away from moisture	
	* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)	

SOLVENT & SOLUBILITY

		Solvent Mass Concentration	1 mg	5 mg	10 mg			
	Preparing Stock Solutions	1 mM	2.1297 mL	10.6485 mL	21.2970 mL			
		5 mM	0.4259 mL	2.1297 mL	4.2594 mL			
		10 mM	0.2130 mL	1.0648 mL	2.1297 mL			
In Vivo		Please refer to the solubility information to select the appropriate solvent. 1. Add each solvent one by one: PBS						
	2. Add each solvent	Solubility: 50 mg/mL (106.48 mM); Clear solution; Need ultrasonic 2. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (5.32 mM); Clear solution						
		3. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (5.32 mM); Clear solution						
		 Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (5.32 mM); Clear solution 						

BIOLOGICAL ACTIVITY

Description

Almotriptan Malate is a 5-HT1B/1D-receptor agonist used to treat migraine.IC50:Target: 5-hydroxytryptamine1B/1D (5-HT1B/1D) ReceptorAlmotriptan Malate is a selective 5-hydroxytryptamine1B/1D (5-HT1B/1D) receptor agonist, used for the treatment of Migraine attacks in adults. Almotriptan showed low nanomolar affinity for the 5-HT(1B) and 5-HT(1D) receptors in several species, including the human, while affinity for 5-HT receptors other than 5-HT(1B/1D) was clearly less. Almotriptan did not exhibit significant affinity for several non-5-HT receptors studied up to 100 microM. Almotriptan inhibited forskolin-stimulated cyclic AMP accumulation in HeLa cells transfected with 5-HT(1B) or 5-HT(1D) human receptors

р он



Product Data Sheet

	probably of no clinical re	ld antiemetic effect and a slight, transient diuretic effect in dogs, although the latter effect is levance. In addition, no effect on the respiratory system of conscious guinea pigs was observed eatment. These results indicate that almotriptan has a favourable safety profile with respect to the d respiratory systems [2].
IC₅₀ & Target	5-HT _{1B} Receptor	5-HT _{1D} Receptor

REFERENCES

[1]. Bou J, et al. Pharmacological characterization of almotriptan: an indolic 5-HT receptor agonist for the treatment of migraine. Eur J Pharmacol, 2000. 410(1): p. 33-41.

[2]. Gras J, et al. Safety profile of almotriptan, a new antimigraine agent. Effects on central nervous system, renal function and respiratory dynamics. Arzneimittelforschung, 2001. 51(9): p. 726-32.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA